Building a successful fertility preservation program at a major cancer center

Journal of Gynecologic Oncology

Volumn 25, Issue 2, 2014, Pages 148-154

  Kim, Jayeon ^a   Kim, Kenneth H ^a   Mersereau, Jennifer E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer center; Fertility preservation; Program

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CONSULTATION; CRYOPRESERVATION; DOCTOR PATIENT RELATION; ENDOMETRIUM CANCER; FERTILITY PRESERVATION; FERTILITY SPECIALIST; FERTILIZATION IN VITRO; GYNECOLOGIC CANCER; HUMAN; INTERPERSONAL COMMUNICATION; LONG TERM SURVIVAL; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; ONCOLOGIST; OVARY CANCER; PATIENT EDUCATION; PATIENT REFERRAL; PROGENY; QUALITY OF LIFE; REVIEW; UTERINE CERVIX CANCER;

EID: 84899135652     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2014.25.2.148     Document Type: Review

References (42)

1. Garvelink MM, Ter Kuile MM, Bakker RM, Geense WJ, Jenninga E, Louwe LA, et al. Women's experiences with information provision and deciding about fertility preservation in the Netherlands: 'satisfaction in general, but unmet needs'. Health Expect 2013 May 5 [Epub]. http://dx. doi. org/10. 1111/hex. 12068.
2. Mayberry RM, Nicewander DA, Qin H, Ballard DJ. Improving quality and reducing inequities: a challenge in achieving best care. World Hosp Health Serv 2008; 44: 16-31.
3. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-10.
4. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat 2013; 137: 571-7.
5. Kim J, Oktay K, Gracia C, Lee S, Morse C, Mersereau JE. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril 2012; 97: 671-6.
6. Balthazar U, Fritz MA, Mersereau JE. Fertility preservation: a pilot study to assess previsit patient knowledge quantitatively. Fertil Steril 2011; 95: 1913-6.
7. Balthazar U, Deal AM, Fritz MA, Kondapalli LA, Kim JY, Mersereau JE. The current fertility preservation consultation model: are we adequately informing cancer patients of their options? Hum Reprod 2012; 27: 2413-9.
8. Matthews ML, Hurst BS, Marshburn PB, Usadi RS, Papadakis MA, Sarantou T. Cancer, fertility preservation, and future pregnancy: a comprehensive review. Obstet Gynecol Int 2012; 2012: 953937.
9. Campo-Engelstein L. Consistency in insurance coverage for iatrogenic conditions resulting from cancer treatment including fertility preservation. J Clin Oncol 2010; 28: 1284-6.
10. D'Amour D, Ferrada-Videla M, San Martin Rodriguez L, Beaulieu MD. The conceptual basis for interprofessional collaboration: core concepts and theoretical frameworks. J Interprof Care 2005; 19 Suppl 1: 116-31.
11. Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril 2010; 94: 1652-6.
12. Goodman LR, Balthazar U, Kim J, Mersereau JE. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod 2012; 27: 2076-81.
13. Kohler TS, Kondapalli LA, Shah A, Chan S, Woodruff TK, Brannigan RE. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. J Assist Reprod Genet 2011; 28: 269-77.
14. Vadaparampil S, Quinn G, King L, Wilson C, Nieder M. Barriers to fertility preservation among pediatric oncologists. Patient Educ Couns 2008; 72: 402-10.
15. Adams E, Hill E, Watson E. Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes. Br J Cancer 2013; 108: 1602-15.
16. Kim J, Deal AM, Balthazar U, Kondapalli LA, Gracia C, Mersereau JE. Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions? Reprod Biomed Online 2013; 27: 96-103.
17. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 2012; 132: 61-73.
18. Manga GP, Shahi PK, Urena MM, Pereira RQ, Plaza MI, Peron YI, et al. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. Breast Cancer 2010; 17: 205-11.
19. Michie S, Dormandy E, Marteau TM. The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns 2002; 48: 87-91.
20. Woolf SH, Chan EC, Harris R, Sheridan SL, Braddock CH 3rd, Kaplan RM, et al. Promoting informed choice: transforming health care to dispense knowledge for decision making. Ann Intern Med 2005; 143: 293-300.
21. Street RL Jr, Voigt B, Geyer C Jr, Manning T, Swanson GP. Increasing patient involvement in choosing treatment for early breast cancer. Cancer 1995; 76: 2275-85.
22. Carlsen B, Aakvik A. Patient involvement in clinical decision making: the effect of GP attitude on patient satisfaction. Health Expect 2006; 9: 148-57.
23. Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology 2006; 15: 9-19.
24. Letourneau JM, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer 2012; 118: 4579-88.
25. Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002; 20: 1880-9.
26. Legare F, O'Connor AC, Graham I, Saucier D, Cote L, Cauchon M, et al. Supporting patients facing difficult health care decisions: use of the Ottawa Decision Support Framework. Can Fam Physician 2006; 52: 476-7.
27. Garvelink MM, ter Kuile MM, Fischer MJ, Louwe LA, Hilders CG, Kroep JR, et al. Development of a Decision Aid about fertility preservation for women with breast cancer in The Netherlands. J Psychosom Obstet Gynaecol 2013; 34: 170-8.
28. Kim J, Oktay K. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control 2013; 24: 421-6.
29. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014; 1: CD001431.
30. Heller L, Parker PA, Youssef A, Miller MJ. Interactive digital education aid in breast reconstruction. Plast Reconstr Surg 2008; 122: 717-24.
31. Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhomme C, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001; 92: 2412-8.
32. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002; 87: 1-7.
33. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 2008; 110: 345-53.
34. Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni A. Role of conservative surgery in ovarian cancer: the European experience. Int J Gynecol Cancer 2005; 15 Suppl 3: 206-11.
35. Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005; 98: 263-6.
36. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007; 25: 2928-37.
37. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90: 434-40.
38. Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol 2001; 83: 388-93.
39. Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol 2001; 22: 217-20.
40. Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002; 94: 2192-8.
41. Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005; 112: 317-20.
42. Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 2003; 91: 569-72.